Insider Selling: Argos Therapeutics Inc (ARGS) Insider Sells 92,001 Shares of Stock

Argos Therapeutics Inc (NASDAQ:ARGS) insider Charles A. Nicolette sold 92,001 shares of the stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $0.16, for a total value of $14,720.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Argos Therapeutics Inc (NASDAQ:ARGS) traded down $0.02 during midday trading on Friday, hitting $0.17. The stock had a trading volume of 6,577,500 shares, compared to its average volume of 6,273,333. The stock has a market cap of $14.07, a PE ratio of -0.15 and a beta of 1.38. The company has a current ratio of 2.29, a quick ratio of 2.29 and a debt-to-equity ratio of -1.46. Argos Therapeutics Inc has a fifty-two week low of $0.13 and a fifty-two week high of $5.68.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. purchased a new position in shares of Argos Therapeutics Inc (NASDAQ:ARGS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned 1.21% of Argos Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 18.35% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply